These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9949803)

  • 1. Recombinant interleukin 2 adjunctive therapy in multidrug-resistant tuberculosis.
    Johnson B; Bekker LG; Ress S; Kaplan G
    Novartis Found Symp; 1998; 217():99-106; discussion 106-11. PubMed ID: 9949803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential gene expression in response to adjunctive recombinant human interleukin-2 immunotherapy in multidrug-resistant tuberculosis patients.
    Johnson BJ; Estrada I; Shen Z; Ress S; Willcox P; Colston MJ; Kaplan G
    Infect Immun; 1998 Jun; 66(6):2426-33. PubMed ID: 9596698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo.
    Johnson BJ; Bekker LG; Rickman R; Brown S; Lesser M; Ress S; Willcox P; Steyn L; Kaplan G
    Tuber Lung Dis; 1997; 78(3-4):195-203. PubMed ID: 9713652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and immune responses of tuberculosis patients treated with low-dose IL-2 and multidrug therapy.
    Johnson BJ; Ress SR; Willcox P; Pati BP; Lorgat F; Stead P; Saha R; Lukey P; Laochumroonvorapong P; Corral L
    Cytokines Mol Ther; 1995 Sep; 1(3):185-96. PubMed ID: 9384675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic effects of recombinant human interleukin 2 as adjunctive immunotherapy against tuberculosis: A systematic review and meta-analysis.
    Zhang R; Xi X; Wang C; Pan Y; Ge C; Zhang L; Zhang S; Liu H
    PLoS One; 2018; 13(7):e0201025. PubMed ID: 30024982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulatory effects of interleukin-2 and interleukin-4 in patients with malignancy.
    Olencki T; Finke J; Tubbs R; Tuason L; Greene T; McLain D; Swanson SJ; Herzog P; Stanley J; Edinger M; Budd GT; Bukowski RM
    J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):69-80. PubMed ID: 8859726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant interferon gamma in patients with drug - resistant pulmonary tuberculosis: a pilot study.
    Suárez-Méndez R; García-García I; Fernández-Olivera N; Valdés-Quintana M; Milanés-Virelles MT; Carbonell D; Machado-Molina D; Valenzuela-Silva CM; López-Saura PA
    BMC Infect Dis; 2004 Oct; 4():44. PubMed ID: 15500691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivo.
    Schneekloth C; Körfer A; Hadam M; Lopez Hänninen E; Menzel T; Schomburg A; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
    Acta Haematol; 1993; 89(1):13-21. PubMed ID: 7683166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with multidrug-resistant tuberculosis with low CD4+ T cell counts have impaired Th1 responses.
    McDyer JF; Hackley MN; Walsh TE; Cook JL; Seder RA
    J Immunol; 1997 Jan; 158(1):492-500. PubMed ID: 8977227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B.
    Carreño V; Zeuzem S; Hopf U; Marcellin P; Cooksley WG; Fevery J; Diago M; Reddy R; Peters M; Rittweger K; Rakhit A; Pardo M
    J Hepatol; 2000 Feb; 32(2):317-24. PubMed ID: 10707873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Combined therapy of pulmonary tuberculosis by using recombinant interleukins].
    Skvortsova LA; Pavlova MV; Vinogradova TI; Archakova LI
    Probl Tuberk Bolezn Legk; 2003; (10):9-12. PubMed ID: 14669620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
    Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine therapy of mycobacterial infections.
    Holland SM
    Adv Intern Med; 2000; 45():431-52. PubMed ID: 10635058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of oral versus intrathymic administration of polymorphic major histocompatibility complex class II peptides on mononuclear and endothelial cell activation and cytokine expression during a delayed-type hypersensitivity response.
    Hancock WW; Khoury SJ; Carpenter CB; Sayegh MH
    Am J Pathol; 1994 Jun; 144(6):1149-58. PubMed ID: 8203456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of different adjuvants on the immune responses of cattle vaccinated with Mycobacterium tuberculosis culture filtrate proteins.
    Wedlock DN; Keen DL; McCarthy AR; Andersen P; Buddle BM
    Vet Immunol Immunopathol; 2002 May; 86(1-2):79-88. PubMed ID: 11943331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profiles of IFN-gamma and its regulatory cytokines (IL-12, IL-18 and IL-10) in peripheral blood mononuclear cells from patients with multidrug-resistant tuberculosis.
    Lee JS; Song CH; Kim CH; Kong SJ; Shon MH; Kim HJ; Park JK; Paik TH; Jo EK
    Clin Exp Immunol; 2002 Jun; 128(3):516-24. PubMed ID: 12067307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycobacterium tuberculosis multi-drug-resistant strain M induces IL-17
    Basile JI; Kviatcovsky D; Romero MM; Balboa L; Monteserin J; Ritacco V; Lopez B; Sabio y García C; García A; Vescovo M; Montaner PG; Palmero D; Del Carmen Sasiain M; de la Barrera S
    Clin Exp Immunol; 2017 Jan; 187(1):160-173. PubMed ID: 27681197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulatory therapy with thymopentin and indomethacin. Successful restoration of interleukin-2 synthesis in patients undergoing major surgery.
    Faist E; Markewitz A; Fuchs D; Lang S; Zarius S; Schildberg FW; Wachter H; Reichart B
    Ann Surg; 1991 Sep; 214(3):264-73; discussion 274-5. PubMed ID: 1929608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot study of natural human interleukin-2 in patients with chronic hepatitis B. Immunomodulatory and antiviral effects.
    Tilg H; Vogel W; Tratkiewicz J; Aulitzky WE; Herold M; Gruber M; Geissler D; Umlauft F; Judmaier G; Schwulera U
    J Hepatol; 1993 Sep; 19(2):259-67. PubMed ID: 8301059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.